Francesco Chiancone

11PUBLICATIONS
18CO-AUTHORS
Cancer cell biologyMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular imaging (incl. electron microscopy and neutron diffraction)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 26, 2026
BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG.

Carlo Buonerba, Raffaele Baio, Felice Crocetto

|Feb 15, 2022
Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.

Maria Lucia Iacovino, Chiara Carmen Miceli, Marco De Felice

|Jul 19, 2021
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy.

Matteo Ferro, Giuseppe Lucarelli, Ottavio de Cobelli

|Jul 14, 2021
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy.

Matteo Ferro, Dragoş-Florin Babă, Ottavio de Cobelli

|Mar 25, 2021
Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette-Guérin failure.

Francesco Chiancone, Marco Fabiano, Maurizio Carrino

|Mar 16, 2021
Laparoscopic versus open partial nephrectomy for the management of highly complex renal tumors with PADUA score ⩾10: A single center analysis.

Francesco Chiancone, Marco Fabiano, Clemente Meccariello

Pageof 2

Frequent Collaborators

2 joint publications

Marco Fabiano

2 joint publications

Felice Crocetto

1 joint publications

Alessandro Izzo

1 joint publications

Matteo Ferro